|
Home : Unsafe Drugs : Avandia : Newsfeeds : Restructuring and Cuts Threaten to Lower Industry R&D Spending Next Year Restructuring and Cuts Threaten to Lower Industry R&D Spending Next Year
The firm believes sales will maintain momentum except for Avandia (facing patent loss), Valtrex (facing competition from generic drugs), and pandemic products. Total sales were down 1% in 2010 over the previous year when those products were included in the ...
Avandia Case Evaluation Form
This form is secure and encrypted. More information about secure forms and your privacy here.
|




